Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm that arises from the ovary and originates from germ cells. Representative examples include teratoma, embryonal carcinoma, yolk sac tumor, and dysgerminoma.
Biomarker and diagnostic research for ovarian germ cell tumor has been reported in the published literature.
8 clinical trials registered, 2 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 5 PHASE2, 1 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04804007](https://clinicaltrials.gov/study/NCT04804007) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
Online Mendelian Inheritance in Man
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT |
PHASE2 |
Nabil Adra |
RECRUITING |
[NCT01696994](https://clinicaltrials.gov/study/NCT01696994) | Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) | NA | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT06276491](https://clinicaltrials.gov/study/NCT06276491) | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | PHASE1 | Xencor, Inc. | RECRUITING |
[NCT02122185](https://clinicaltrials.gov/study/NCT02122185) | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PHASE2 | University of Chicago | UNKNOWN |
[NCT02834013](https://clinicaltrials.gov/study/NCT02834013) | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
141 publications have been identified in PubMed for ovarian germ cell tumor. Research spans Case Report / Case Series (42%), Review / Meta-Analysis (25%), and Diagnostic / Biomarker (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 59 | 42% |
Research summaries | 35 | 25% |
Testing and diagnosis research | 15 | 11% |
Laboratory research | 14 | 10% |
Disease patterns and progression | 13 | 9% |
Clinical study results | 3 | 2% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Tamauchi S (2026). [PMID: 41531187](https://pubmed.ncbi.nlm.nih.gov/41531187/). *Cancer Sci*. [Gene Therapy / Novel Therapeutics]
Lin LH (2026). [PMID: 41498302](https://pubmed.ncbi.nlm.nih.gov/41498302/). *Histopathology*. [Diagnostic / Biomarker]
Cao J (2026). [PMID: 41088975](https://pubmed.ncbi.nlm.nih.gov/41088975/). *Curr Med Imaging*. [Case Report / Case Series]
Rodríguez-Rubio Corona C (2026). [PMID: 41933956](https://pubmed.ncbi.nlm.nih.gov/41933956/). *Int J Gynecol Cancer*. [Case Report / Case Series]
Gupta A (2026). [PMID: 40991421](https://pubmed.ncbi.nlm.nih.gov/40991421/). *Int J Gynecol Pathol*. [Review / Meta-Analysis]
Sadiq Q (2026). [PMID: 32644667](https://pubmed.ncbi.nlm.nih.gov/32644667/). *Unknown Journal*. [Review / Meta-Analysis]
Dey S (2026). [PMID: 42210622](https://pubmed.ncbi.nlm.nih.gov/42210622/). *Cancer Med*. [Epidemiology / Natural History]
Tanoglu FB (2026). [PMID: 41217379](https://pubmed.ncbi.nlm.nih.gov/41217379/). *Int J Gynecol Pathol*. [Review / Meta-Analysis]
Abdelwahed A (2026). [PMID: 41739995](https://pubmed.ncbi.nlm.nih.gov/41739995/). *Adv Sci (Weinh)*. [Diagnostic / Biomarker]
Michalik-Jarczyńska K (2026). [PMID: 42015720](https://pubmed.ncbi.nlm.nih.gov/42015720/). *Pol Przegl Chir*. [Review / Meta-Analysis]